Clinical efficacy and safety of statins in managing cardiovascular risk
Authors Kapur NK, Musunuru K
Published 11 April 2008 Volume 2008:4(2) Pages 341—353
Navin K Kapur1, Kiran Musunuru2
1Division of Cardiology, Tufts University – New England Medical Center; Boston, MA, USA; 2Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Abstract: Since their introduction in the 1980s, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling medication classes to date, with numerous trials demonstrating powerful efficacy in preventing cardiovascular outcomes. As our understanding of low-density lipoprotein cholesterol (LDL-C) and atherosclerosis continues to grow, the concept of ‘lower is better’ has corresponded with a ‘more is better’ approach to statin-based therapy. This review provides a detailed understanding of the clinical efficacy and safety of statins with a particular emphasis on the third generation drug, rosuvastatin.
Keywords: low density lipoprotein cholesterol (LDL-C), efficacy, safety, HMGCo-A reductase inhibitors, rosuvastatin
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]